Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

医学 银屑病性关节炎 类风湿性关节炎 强直性脊柱炎 贾纳斯激酶 银屑病 抗风湿药 持久性(不连续性) 关节炎 肿瘤坏死因子α 内科学 皮肤病科 肿瘤科 免疫学 受体 岩土工程 工程类
作者
Blanca Hernández‐Cruz,Lucia Otero Varela,Mercedes Freire-González,Noemí Busquets-Pérez,A González,Manuel José Moreno Ramos,J. M. Blanco-Madrigal,Sara Manrique‐Arija,Eva Pérez‐Pampín,D. Ruiz-Montesinos,Fernando Sánchez‐Alonso,Carlos Sánchez‐Piedra,Isabel Castrejón
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: ard-225271 被引量:3
标识
DOI:10.1136/ard-2023-225271
摘要

Objectives To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Methods We analysed data from patients included in BIOBADASER 3.0 and treated with JAKi or TNFi from 2015 to 2023 and estimated the incidence rate ratio (IRR) of adverse events and persistence. Results A total of 6826 patients were included. Of these, 52% had RA, 25% psoriatic arthritis and 23% axial SpA. Treatment was with TNFi in 86%. The mean duration of treatment was 2.2±2.0 years with TNFi versus 1.8±1.5 with JAKi. JAKis were prescribed in older patients with longer term disease, greater comorbidity and later treatment lines and more frequently as monotherapy. The IRR of all infections and gastrointestinal events was higher among patients with RA treated with JAKi. Drug persistence at 1, 2 and 3 years was 69%, 55% and 45% for TNFi and 68%, 54% and 45% for JAKi. Multivariate regression models showed a lower probability of discontinuation for JAKi (HR=0.85; 95% CI 0.78–0.92) and concomitant conventional synthetic disease-modifying antirheumatic drugs (HR=0.90; 95% CI 0.84–0.96). The risk of discontinuation increased with glucocorticoids, comorbidities, greater disease activity and later treatment lines. Conclusions Infections, herpes zoster and gastrointestinal adverse events in patients with RA tended to be more frequent with JAKi. However, prognosis was poor in patients receiving JAKi. Persistence was similar for TNFi and JAKi, although factors associated with discontinuation differed by diagnostic group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
3秒前
小二郎应助高手采纳,获得10
3秒前
4秒前
民科王聪发布了新的文献求助10
4秒前
4秒前
YaoZhang完成签到 ,获得积分10
5秒前
潇湘雪月发布了新的文献求助10
6秒前
7秒前
如意枫叶发布了新的文献求助10
7秒前
Rondab应助卡卡罗特采纳,获得10
10秒前
14秒前
18秒前
19秒前
芋孟齐发布了新的文献求助10
19秒前
23秒前
23秒前
一路生花完成签到,获得积分10
23秒前
orixero应助小慧儿采纳,获得10
23秒前
Ava应助科研通管家采纳,获得10
23秒前
23秒前
SYLH应助科研通管家采纳,获得10
23秒前
田様应助科研通管家采纳,获得10
24秒前
丘比特应助科研通管家采纳,获得10
24秒前
潇湘雪月发布了新的文献求助10
24秒前
今后应助科研通管家采纳,获得10
24秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
情怀应助科研通管家采纳,获得10
24秒前
打打应助科研通管家采纳,获得10
24秒前
24秒前
香蕉觅云应助科研通管家采纳,获得10
24秒前
24秒前
斯文败类应助科研通管家采纳,获得10
24秒前
wanci应助科研通管家采纳,获得10
24秒前
24秒前
爆米花应助科研通管家采纳,获得10
24秒前
SYLH应助科研通管家采纳,获得30
24秒前
星辰大海应助科研通管家采纳,获得10
24秒前
栗惠完成签到 ,获得积分20
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136